Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Operating Expenses: 2016-2024

Historic Operating Expenses for Protagonist Therapeutics (PTGX) over the last 9 years, with Dec 2024 value amounting to $181.6 million.

  • Protagonist Therapeutics' Operating Expenses rose 10.85% to $51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.2 million, marking a year-over-year increase of 8.89%. This contributed to the annual value of $181.6 million for FY2024, which is 18.18% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Operating Expenses of $181.6 million as of FY2024, which was up 18.18% from $153.7 million recorded in FY2023.
  • Protagonist Therapeutics' 5-year Operating Expenses high stood at $181.6 million for FY2024, and its period low was $93.1 million during FY2020.
  • In the last 3 years, Protagonist Therapeutics' Operating Expenses had a median value of $158.0 million in 2022 and averaged $164.4 million.
  • As far as peak fluctuations go, Protagonist Therapeutics' Operating Expenses surged by 64.48% in 2021, and later dropped by 2.72% in 2023.
  • Over the past 5 years, Protagonist Therapeutics' Operating Expenses (Yearly) stood at $93.1 million in 2020, then skyrocketed by 64.48% to $153.2 million in 2021, then grew by 3.10% to $158.0 million in 2022, then fell by 2.72% to $153.7 million in 2023, then rose by 18.18% to $181.6 million in 2024.